News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Elyse Hall Panjic, PharmD, BCOP

Articles by Elyse Hall Panjic, PharmD, BCOP

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

ByAlexandra Vitko,Pamela K Ginex,Kelli Thoele,Qinli Lily Ma,Astra Liepa,Wambui Gathirua-Mwangi,Elyse Hall Panjic, PharmD, BCOP,Engels Chou,Jodi L Taraba,Hilary Ellis,Charlotte Clewes,Joanna de Courcy,Hope S. Rugo, MD

April 15th 2025

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis

ByKevin H. Hall, PharmD, BCOP,Elyse Hall Panjic, PharmD, BCOP,Kelly Valla, PharmD, BCOP,Christopher R. Flowers, MD, MS,Jonathon B. Cohen, MD, MS

June 15th 2018

Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.

Latest Updated Articles

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis
Published: June 15th 2018 | Updated:

Trending on CancerNetwork

FDA OKs Study Progression of (Z)-Endoxifen in Metastatic Breast Cancer

Subcutaneous Isatuximab Regimens Show Efficacy in R/R Multiple Myeloma

BI-1808 Combo Improves Efficacy vs Pembrolizumab Alone in Ovarian Cancer

Intravenous Olvi-Vec Yields Responses in NSCLC and SCLC Following Progression

Recurrence Rates Higher With Axillary Lymph Node Biopsy After NAT Chemotherapy